Award
Alnylam Pharmaceuticals 09/01/2026 - 08/31/2031
- Awarded to
- Not stated
- Agency
- Nac Federal Supply Schedule (36F797)
- Estimated value
- $387,844,840
Key dates
- Award date
- August 11, 2026
- Posted
- August 12, 2026
Who is this buyer
Organization
Buying history
- Records51 total
- Opportunities / awards1 / 50
- Value range$0 – $5,600,000,000
- ActiveJuly 16, 2026 – October 26, 2026
What they buy
- Clinical (51)
Set-asides used
- No Set aside used (1)
Who holds their work today
- SUMITOMO PHARMA AMERICA, INC.2 wins · $5,790,675,920 · last August 24, 2026
- BAUSCH HEALTH US LLC1 win · $3,680,000,000 · last September 14, 2026
- GENZYME CORPORATION1 win · $670,000,000
- DECIPHERA PHARMACEUTICALS, LLC2 wins · $367,600,000 · last September 24, 2026
- VIVUS LLC1 win · $285,661,720 · last September 17, 2026
Also open from this buyer
- Department of Veterans Affairs Pharmaceutical Industry DayDue November 20, 2026 · Clinical
Ways to meet this buyer
Upcoming
- November 20, 2026Industry day
Department of Veterans Affairs Pharmaceutical Industry Day
RegisterSAM.gov notice — Nac Federal Supply Schedule (36F797)
View source document →
Source link on sam.gov.
Source record
- Buyer type
- Federal
- Jurisdiction
- Federal (US)
- Category
- Clinical
- Set-aside
- Not stated
- NAICS
- 325412
- PSC
- 6505